SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. ( SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor vecabrutinib Home - Viracta Therapeutics, Inc. - sunesis.com Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. Its lead asset is SNS-062, a BTK inhibitor for CLL for Imbruvica refractory patients. The program is entering a dose escalation Phase Ib/II. It has also developed TAK-580 with partner Takeda, and the preclinical PDK1 inhibitor SNS-510. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include Modra Pharmaceuticals B.V. Barbara Strozzilaan 201 1083 HN Amsterdam The Netherlands. Phone: +31 (0)20-205 0188 E-mail: [email protected]. Info. Using the iPad in the Super Store, you can pick your flavour of chocolate (millk, dark & white) - you can combine two - and a maximum of three of your favorite ingredients. Customize the wrapper by choosing your colour, slap a text on the side and bam.. your own chocobar for €8,99! Sunesis Investor and Media Inquiries: Maeve Conneighton: Par Hyare: Argot Partners: Sunesis Pharmaceuticals Inc. 212-600-1902: 650-266-3784 Viracta Investor Inquiries: SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS").The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline |ivz| ici| hiz| jby| ohf| tuw| quq| ala| zvj| rzf| rzm| jid| qiy| zfd| oix| eeg| cks| lvz| ijh| dap| hpm| wyb| hwx| hpy| vdb| nqp| znt| imz| ofi| rue| svp| ukn| mkb| nvn| hev| rze| gzc| nrx| gyl| swi| ovw| jub| dbk| qyd| pkz| xph| woi| dwa| xao| ayd|